posted by Alicia Caramenico
on September 1, 2016
AHIP’s Matt Eyles: “We have not yet heard the CEO of Mylan really address the issue of why the price is what is it. How do they justify getting to a price of $600? They can’t.”
Yesterday on Fox Business, AHIP Executive Vice President Matt Eyles discussed Mylan’s egregious pricing and the impact on patient costs. The Fox Business segment also looked at Mylan’s move to offer a generic version and discount programs for the EpiPen.
“When you have real generic competition, you have prices that drop by 80 or 90 percent. This is really more of a shell game or gimmick to try and deflect attention away from the real issue, which is the price of the product.”
“… They’re just trying to mix and match issues, when the issue would be addressed if they would just reduce the price of the product to a reasonable level.
The controversy surrounding the EpiPen’s price skyrocketing more than 500 percent highlights the pervasive problem of drugmakers raising their prices without any justification.
You can watch the full story, “Is Mylan doing enough to offset EpiPen costs?” below.